Factor V Leiden Genotype Therapy for VTE Risk Without Bleeding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Individuals with Factor V Leiden (FVL) variant have an increased risk of venous thromboembolism (VTE) during anticoagulant treatment, with standard therapies potentially increasing bleeding risk.
Innovation Solution
Determine FVL genotype through sequence analysis and either selectively deplete FVL in heterozygotes or replace it with a functioning Factor V gene in homozygotes to reduce VTE risk, using inhibitory nucleic acids or genetic editing techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard anti-coagulant therapies are used in FVL carriers, then VTE risk is reduced, but bleeding risk increases
Solution Approach 1:
The patent applies selective depletion of FVL using inhibitory nucleic acid molecules (siRNA, antisense oligonucleotides) to specifically remove the pathological factor V Leiden protein while preserving normal factor V function. This extraction approach targets only the harmful FVL variant for degradation, thereby reducing VTE risk without causing the systemic bleeding complications associated with broad-spectrum anticoagulants
Solution Approach 2:
The invention implements local quality by using genotype-directed therapy where heterozygous FVL carriers receive selective FVL depletion while homozygous carriers receive gene replacement therapy. This personalized approach tailors the therapeutic intervention to the specific genetic status of each patient, optimizing efficacy while minimizing bleeding risk through precision medicine
2Reliability
If FVL is selectively depleted in heterozygotes, then VTE risk is reduced without increasing bleeding risk, but the treatment complexity increases
Solution Approach 1:
The patent implements preliminary action by performing genotype analysis (sequence analysis) on a biological sample before initiating therapy. This preliminary genetic characterization identifies whether the patient is heterozygous or homozygous for FVL, enabling selection of the appropriate therapeutic strategy (selective depletion vs. gene replacement) before treatment begins, thereby simplifying the overall treatment pathway through advance patient stratification
3Reliability
If FVL is replaced with a functioning Factor V gene in homozygotes, then APC resistance is corrected, but the treatment complexity increases
Solution Approach 1:
The patent applies parameter changes by using CRISPR-Cas9 gene editing to directly modify the FVL gene sequence in homozygous carriers, changing the pathological glutamine codon back to the wild-type arginine codon. This parameter change at the DNA level restores normal APC cleavage activity and corrects the underlying genetic defect, providing a curative rather than merely symptomatic treatment
Data Source
AI summary
Methods of reducing the risk of venous thromboembolism (VTE) in a subject undergoing anticoagulant treatment by selectively depleting Factor V Leiden (FVL) in a subject that is heterozygous for FVL, or replacing FVL in the genome of a subject that is homozygous for FVL with a functional Factor V gene, and methods of identifying a subject undergoing anticoagulant treatment who is at risk of developing VTE are disclosed herein.